WHAT IS CLAIMED IS:

1. A compound having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein:

A is selected from the group consisting of:

phenyl, pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl;

B is selected from the group consisting of:

phenyl, pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl;

Het-CH_2-R^3 is selected from the group consisting of:



;

M has the formula:



wherein

L^1 is a bond or C_{1-6} alkyl optionally substituted with one or more R^4 groups;

L^2 is a bond or C_{1-6} alkyl optionally substituted with one or more R^4 groups;

Q is selected from the group consisting of:

a) H, b) -NR^4R^4, c) -OR^4, and d) C_{1-6} alkyl optionally substituted with one or more R^4 groups; and

W is selected from the group consisting of O and S;

X is selected from the group consisting of:

a) -NR^4-, b) -NR^4NR^4-, and c) -S-;

L is C_{1-6} alkyl optionally substituted with one or more R^4 groups;

R^1, at each occurrence, independently is selected from the group consisting of:

a) F, b) Cl, c) Br, d) I, e) $-CF_3$, f) $-OR^7$, g) -CN, h) $-NO_2$, i) $-NR^7R^7$, j) $-C(O)R^7$, k) $-C(O)OR^7$, l) $-OC(O)R^7$, m) $-C(O)NR^7R^7$, n) $-NR^7C(O)R^7$, o) $-OC(O)NR^7R^7$, p) $-NR^7C(O)OR^7$, q) $-NR^7C(O)NR^7R^7$, r) $-C(S)R^7$, s) $-C(S)OR^7$, t) $-OC(S)R^7$, u) $-C(S)NR^7R^7$, v) $-NR^7C(S)R^7$, w) $-OC(S)NR^7R^7$, x) $-NR^7C(S)OR^7$, y) $-NR^7C(S)NR^7R^7$, z) $-C(NR^7)R^7$, aa) $-C(NR^7)OR^7$, bb) $-OC(NR^7)R^7$, cc) $-C(NR^7)NR^7R^7$, dd) $-NR^7C(NR^7)R^7$, ee) $-OC(NR^7)NR^7R^7$, ff) $-NR^7C(NR^7)OR^7$, gg) $-NR^7C(NR^7)NR^7R^7$, hh) $-S(O)_pR^7$, ii) $-SO_2NR^7R^7$, and jj) R^7;

R^2, at each occurrence, independently is selected from the group consisting of:

a) F, b) Cl, c) Br, d) I, e) $-CF_3$, f) $-OR^7$, g) -CN, h) $-NO_2$, i) $-NR^7R^7$, j) $-C(O)R^7$, k) $-C(O)OR^7$, l) $-OC(O)R^7$, m) $-C(O)NR^7R^7$, n) $-NR^7C(O)R^7$, o) $-OC(O)NR^7R^7$, p) $-NR^7C(O)OR^7$, q) $-NR^7C(O)NR^7R^7$, r) $-C(S)R^7$, s) $-C(S)OR^7$, t) $-OC(S)R^7$, u) $-C(S)NR^7R^7$, v) $-NR^7C(S)R^7$, w) $-OC(S)NR^7R^7$, x) $-NR^7C(S)OR^7$, y) $-NR^7C(S)NR^7R^7$, z) $-C(NR^7)R^7$, aa) $-C(NR^7)OR^7$, bb) $-OC(NR^7)R^7$, cc) $-C(NR^7)NR^7R^7$, dd) $-NR^7C(NR^7)R^7$, ee) $-OC(NR^7)NR^7R^7$, ff) $-NR^7C(NR^7)OR^7$, gg) $-NR^7C(NR^7)NR^7R^7$, hh) $-S(O)_pR^7$, ii) $-SO_2NR^7R^7$, and jj) R^7;

R^3 is selected from the group consisting of:

a) $-OR^7$, b) $-NR^7R^7$, c) $-C(O)R^7$, d) $-C(O)OR^7$, e) $-OC(O)R^7$, f) $-C(O)NR^7R^7$, g) $-NR^7C(O)R^7$, h) $-OC(O)NR^7R^7$, i) $-NR^7C(O)OR^7$, j) $-NR^7C(O)NR^7R^7$, k) $-C(S)R^7$, l) $-C(S)OR^7$, m) $-OC(S)R^7$, n) $-C(S)NR^7R^7$, o) $-NR^7C(S)R^7$, p) $-OC(S)NR^7R^7$, q) $-NR^7C(S)OR^7$, r) $-NR^7C(S)NR^7R^7$, s) $-C(NR^7)R^7$, t) $-C(NR^7)OR^7$, u) $-OC(NR^7)R^7$, v) $-C(NR^7)NR^7R^7$, w) $-NR^7C(NR^7)R^7$, x) $-OC(NR^7)NR^7R^7$, y) $-NR^7C(NR^7)OR^7$, z) $-NR^7C(NR^7)NR^7R^7$, aa) $-S(O)_pR^7$, bb) $-SO_2NR^7R^7$, and cc) R^7;

R^4, at each occurrence, independently is selected from the group consisting of:

a) H, b) =O, c) =S, d) $=NR^5$, e) $=NOR^5$, f) $=N\text{-}NR^5R^5$, g) $-OR^5$, h) $-NO_2$, i) $-NR^5R^5$, j) $-C(O)R^5$, k) $-C(O)OR^5$, l) $-OC(O)R^5$, m) $-C(O)NR^5R^5$, n) $-NR^5C(O)R^5$, o) $-OC(O)NR^5R^5$, p) $-NR^5C(O)OR^5$, q) $-NR^5C(O)NR^5R^5$, r) $-C(S)R^5$,

s) -C(S)OR^5, t) -OC(S)R^5, u) -C(S)NR^{5}R^5, v) -NR^{5}C(S)R^5, w) -OC(S)NR^{5}R^5, x) –NR^{5}C(S)OR^5, y) -NR^{5}C(S)NR^{5}R^5, z) -C(NR^5)R^5, aa) -C(NR^5)OR^5, bb) -OC(NR^5)R^5, cc) -C(NR^5)NR^{5}R^5, dd) -NR^{5}C(NR^5)R^5, ee) -OC(NR^5)NR^{5}R^5, ff) -NR^{5}C(NR^5)OR^5, gg) -NR^{5}C(NR^5)NR^{5}R^5, hh) -S(O)$_p$R^5, and ii) R^5;

R^5, at each occurrence, independently is selected from the group consisting of:

a) H, b) C$_{1-6}$ alkyl, c) -C(O)-C$_{1-6}$ alkyl, and d) -C(O)O-C$_{1-6}$ alkyl,

wherein any of b) – d) optionally is substituted with one or more R^6 groups;

R^6, at each occurrence, independently is selected from the group consisting of:

a) –OH, b) –OC$_{1-6}$ alkyl, c) -SH, d) -NO$_2$, e) –NH$_2$, f) -NHC$_{1-6}$ alkyl, g) -N(C$_{1-6}$ alkyl)$_2$, h) –C(O)H, i) –C(O)OH, j) -C(O)C$_{1-6}$ alkyl, k) -OC(O)C$_{1-6}$ alkyl, l) -C(O)OC$_{1-6}$ alkyl, m) -C(O)NH$_2$, n) –C(O)NHC$_{1-6}$ alkyl, o) -C(O)N(C$_{1-6}$ alkyl)$_2$, p) -NHC(O)C$_{1-6}$ alkyl, and q) -S(O)$_p$C$_{1-6}$ alkyl;

R^7, at each occurrence, independently is selected from the group consisting of:

a) H, b) C$_{1-6}$ alkyl, c) C$_{2-6}$ alkenyl, d) C$_{2-6}$ alkynyl, e) C$_{3-14}$ saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, g) -C(O)-C$_{1-6}$ alkyl, h) -C(O)-C$_{2-6}$ alkenyl, i) –C(O)-C$_{2-6}$ alkynyl, j) -C(O)-C$_{3-14}$ saturated, unsaturated, or aromatic carbocycle, k) -C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, l) -C(O)O-C$_{1-6}$ alkyl, m) -C(O)O-C$_{2-6}$ alkenyl, n) –C(O)O-C$_{2-6}$ alkynyl, o) -C(O)O-C$_{3-14}$ saturated, unsaturated, or aromatic carbocycle, and p) -C(O)O-3-14 membered saturated, unsaturated, or aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

wherein any of b) – p) optionally is substituted with one or more R^8 groups;

R^8, at each occurrence, is independently selected from the group consisting of:

a) F, b) Cl, c) Br, d) I, e) =O, f) =S, g) =NR^9, h) =NOR^9, i) =N-NR^{9}R^9, j) -CF$_3$, k) –OR^9, l) -CN, m) -NO$_2$, n) –NR^{9}R^9, o) -C(O)R^9, p) -C(O)OR^9, q) -OC(O)R^9, r) -C(O)NR^{9}R^9, s) –NR^{9}C(O)R^9, t) -OC(O)NR^{9}R^9, u) –NR^{9}C(O)OR^9, v) -NR^{9}C(O)NR^{9}R^9, w) -C(S)R^9, x) -C(S)OR^9, y) -OC(S)R^9, z) -C(S)NR^{9}R^9, aa) -NR^{9}C(S)R^9, bb) -OC(S)NR^{9}R^9, cc) –NR^{9}C(S)OR^9, dd) –NR^{9}C(S)NR^{9}R^9,

ee) -$C(NR^9)R^9$, ff) -$C(NR^9)OR^9$, gg) -$OC(NR^9)R^9$, hh) -$C(NR^9)NR^9R^9$,
ii) -$NR^9C(NR^9)R^9$, jj) -$OC(NR^9)NR^9R^9$, kk) –$NR^9C(NR^9)OR^9$,
ll) -$NR^9C(NR^9)NR^9R^9$, mm) -$S(O)_pR^9$, nn) -$SO_2NR^9R^9$, and oo) R^9;

R^9, at each occurrence, independently is selected from the group consisting of:
a) H, b) C_{1-6} alkyl, c) C_{2-6} alkenyl, d) C_{2-6} alkynyl, e) C_{3-14} saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, g) -C(O)-C_{1-6} alkyl, h) -C(O)-C_{2-6} alkenyl, i) –C(O)-C_{2-6} alkynyl, j) -C(O)-C_{3-14} saturated, unsaturated, or aromatic carbocycle, k) -C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, l) -C(O)O-C_{1-6} alkyl, m) -C(O)O-C_{2-6} alkenyl, n) –C(O)O-C_{2-6} alkynyl, o) -C(O)O-C_{3-14} saturated, unsaturated, or aromatic carbocycle, and p) -C(O)O-3-14 membered saturated, unsaturated, or aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

wherein any of b) – p) optionally is substituted with one or more moieties selected from the group consisting of:

a) F, b) Cl, c) Br, d) I, e) -CF_3, f) –OH, g) –OC_{1-6} alkyl, h) -SH, i) -SC_{1-6} alkyl, j) -CN, k) -NO_2, l) –NH_2, m) –NHC_{1-6} alkyl, n) -$N(C_{1-6}$ alkyl$)_2$, o) -$C(O)C_{1-6}$ alkyl, p) -$OC(O)C_{1-6}$ alkyl, q) -$C(O)OC_{1-6}$ alkyl, r) -$C(O)NH_2$, s) –$C(O)NHC_{1-6}$ alkyl, t) -$C(O)N(C_{1-6}$ alkyl$)_2$, u) -$NHC(O)C_{1-6}$ alkyl, v) -SO_2NH_2-, w) -SO_2NHC_{1-6} alkyl, x) -$SO_2N(C_{1-6}$ alkyl$)_2$, and y) -$S(O)_pC_{1-6}$ alkyl;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, 3, or 4; and

p, at each occurrence, independently is 0, 1, or 2,

and wherein the compound does not have the formula selected from the group consisting of:



116 ,



117 , and



118 .

1 2. The compound according to claim 1, having the formula:



2

3 or a pharmaceutically acceptable salt, ester or prodrug thereof,

4 wherein A, B, L, M, R^1, R^2, R^3, X, m, and n are defined as described in claim 1.

1 3. The compound according to claim 1 or 2, having the formula:



2

3 or a pharmaceutically acceptable salt, ester or prodrug thereof,

4 wherein A, B, L, M, R^1, R^2, R^3, X, m, and n are defined as described in claim 1.

1 4. The compound according to any one of claims 1-3, wherein

2 A is selected from the group consisting of phenyl and pyridyl;

3 B is selected from the group consisting of phenyl and pyridyl;

4 m is 0, 1, or 2; and

n is 0, 1, or 2.

5. The compound according to any one of claims 1-4, wherein A-B is:



wherein A, R^2, and n are defined as described in claim 1.

6. The compound according to claim 5, wherein A-B is:



wherein A is defined as described in claim 1.

7. The compound according to claim 5, wherein A-B is:



wherein A is defined as described in claim 1.

8. The compound according to any one of claims 1-7, wherein A-B is:



wherein B is defined as described in claim 1.

9. The compound according to any one of claims 1-7, wherein A-B is:



wherein B is defined as described in claim 1.

10. The compound according to any one of claims 1-9, wherein R^3 is $-NHC(O)R^7$.

11. The compound according to claim 10, wherein R^3 is $-NHC(O)CH_3$.

12. The compound according to any one of claims 1-9, wherein R^3 is:



13. The compound according to claim 1 or 2, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein A, B, L, M, R^1, R^2, X, m, and n are defined as described in claim 1.

14. The compound according to claim 1 or 2, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein A, L, M, R^1, R^3, X, and m are defined as described in claim 1.

15. The compound according to claim 14, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein A, L, M, R^1, X, and m are defined as described in claim 1.

16. The compound according to claim 14, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, R^3, and X are defined as described in claim 1.

17. The compound according to claim 16, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, and X are defined as described in claim 1.

18. The compound according to claim 14, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, R^3, and X are defined as described in claim 1.

19. The compound according to claim 18, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, and X are defined as described in claim 1.

20. The compound according to claim 1 or 2, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein A, L, M, R^1, R^3, X, and m are defined as described in claim 1.

21. The compound according to claim 20, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein A, L, M, R^1, X, and m are defined as described in claim 1.

22. The compound according to claim 20, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, R^3, and X are defined as described in claim 1.

23. The compound according to claim 22, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, and X are defined as described in claim 1.

24. The compound according to claim 20, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, R^3, and X are defined as described in claim 1.

25. The compound according to claim 24, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, and X are defined as described in claim 1.

26. The compound according to any one of claims 1-25, wherein M is:



and R^4, at each occurrence, independently is defined as described in claim 1.

27. The compound according to claim 26, wherein M is:



and R^4 is defined as described in claim 1.

28. The compound according to any one of claims 1-25, wherein M is:



and R^4, at each occurrence, independently is defined as described in claim 1.

29. The compound according to claim 28, wherein M is:



and R^4 is defined as described in claim 1.

30. The compound according to any one of claims 1-29, wherein X is –NH-.

31. The compound according to any one of claims 1-29, wherein X is:

32. A compound having the structure corresponding to any one of the structures listed in Table 1, or a pharmaceutically acceptable salt, ester, or prodrug thereof.

33. A pharmaceutical composition comprising one or more compounds according to any one of claims 1-32 and a pharmaceutically acceptable carrier.

34. A method of treating a microbial infection in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to any one of claims 1-32.

35. A method of treating a fungal infection in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to any one of claims 1-32.

36. A method of treating a parasitic disease in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to any one of claims 1-32.

37. A method of treating a proliferative disease in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to any one of claims 1-32.

38. A method of treating a viral infection in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to any one of claims 1-32.

39. A method of treating an inflammatory disease in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to any one of claims 1-32.

40. A method of treating a gastrointestinal motility disorder in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to any one of claims 1-32.

41. A method of treating a disorder in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to any one of claims 1-32 thereby to ameliorate a symptom of the disorder, wherein the disorder is selected from the group consisting of:

a skin infection, nosocomial pneumonia, post-viral pneumonia, an abdominal infection, a urinary tract infection, bacteremia, septicemia, endocarditis, an atrio-ventricular shunt infection, a vascular access infection, meningitis, surgical prophylaxis, a peritoneal infection, a bone infection, a joint infection, a methicillin-resistant *Staphylococcus aureus* infection, a vancomycin-resistant *Enterococci* infection, a linezolid-resistant organism infection, and tuberculosis.

42. The method according to any one of claims 34-41, wherein the compound is administered orally, parentally, or topically.

43. A method of synthesizing a compound according to any one of claims 1-32.

44. A medical device containing one or more compounds according to any one of claims 1-32.

45. The medical device according to claim 44, wherein the device is a stent.